Real-world Survival Outcomes in Patients with Locally Advanced or Metastatic NTRK Fusion-Positive Solid Tumors Receiving Standard-of-care Therapies Other Than Targeted TRK Inhibitors.
PLoS ONE（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要
PLoS ONE（2022）